39 results
Thumbnail

D2.151 - HZ-Y030, an Oral STAT6 Degrader, Attenuates Type 2 Inflammation in Preclinical Asthma Models

Thumbnail

D2.152 - Clinical and functional characteristics of patients with suspected epoxy resin-related occupational asthma

Thumbnail

D2.155 - Mapping the Architecture and Spectrum of the Cough Hypersensitivity Questionnaire Across Respiratory Diseases

Thumbnail

D2.158 - Circulating 1-methylnicotinamide can predict the treatment response of dupilumab in adult asthma

Thumbnail

D2.149 - Occupational asthma in a tea-packaging worker: a case report

Thumbnail

D2.150 - Clinical and functional outcomes after the diagnosis of baker’s asthma: ended vs. reduced exposure

Thumbnail

D2.154 - Small airway dysfunction defined by reduced FEF25–75% identifies a distinct clinical phenotype in children with preserved FEV1

Thumbnail

D2.156 - Defining the Systemic Boundary Between N-ERD and EGPA: Avoiding Misclassification of Eosinophilic Diseases

Thumbnail

D2.157 - Clinical remission with tezepelumab in severe asthma: prevalence and predictors in a real-world multicentre study

Thumbnail

D2.159 - Idiopathic Chronic Eosinophilic Pneumonia: A Case Series

Thumbnail

D2.160 - Household Overcrowding and Number of Siblings as Risk Factors for Uncontrolled Asthma in Inner-City Children

Thumbnail

D2.161 - Exploring the Early-Life Interplay Between Respiratory Health and Neurodevelopmental disorders

Thumbnail

D3.213 - Sustained effectiveness of the 300 IR house dust mite sublingual tablet over 2 treatment years in a real-world data setting – results of a non-interventional study

Thumbnail

D3.198 - Challenges of using clinical scores as primary endpoints in allergology trials

Thumbnail

D3.199 - Severe systemic allergic reaction following violation of elimination diet in a patient with sensitization despite achieved remission on allergen-specific immunotherapy

Thumbnail

D3.200 - Broad profile of olive pollen sensitisation as a key factor in immunotherapy failure

Thumbnail

D3.201 - Subcutaneous immunotherapy with a depigmented cat allergoid is safe in patients with cat allergy and beneficial for mental health in adolescents

Thumbnail

D3.202 - Characterising relevant major allergens beyond modification: from allergen to allergoid

Thumbnail

D3.203 - Characterisation of relevant allergens in grass pollen extracts

Thumbnail

D3.205 - Two-year Outcomes of Multiple Low-Dose Oral Immunotherapies for combination of Tree Nuts or Peanut for Severe Allergy Patients